Caplacizumab is a nano-antibody drug used to treat acquired thrombotic thrombocytopenic purpura (aTTP) in adults. It reduces platelet consumption by blocking the interaction between von Willebrand factor (vWF) and platelets.
Instructions for Caplacizumab: Actions and Efficacy
Caplacizumab is an innovative nano-antibody drug specifically used to treat acquired thrombotic thrombocytopenic purpura (aTTP) in adults. Its unique mechanism of action provides patients with a new treatment option.
Mechanism of Action
Caplacizumab effectively reduces vWF-mediated platelet adhesion and consumption by specifically blocking the interaction between von Willebrand factor (vWF) and platelets. This mechanism can rapidly improve microvascular thrombosis in patients with aTTP, thereby alleviating the condition.
Clinical efficacy
Clinical studies have shown that Caplacizumab combined with plasma exchange and immunosuppressive therapy can significantly shorten the time for platelet count recovery, reduce the recurrence rate of the disease, and reduce the number of days and plasma usage of plasma exchange. These advantages bring better treatment effects and quality of life to patients.
The unique mechanism of action and obvious clinical effects of Caplacizumab make it an important drug in the treatment of aTTP. The following will introduce its usage and dosage in detail to help patients and medical staff use it correctly.
Usage and dosage of Caplacizumab
The use of Caplacizumab must strictly follow the recommended dose and administration method to clarify the therapeutic effect and reduce the occurrence of adverse reactions.
Recommended dose
The initial dose of Caplacizumab is 11 mg intravenous injection, which must be completed at least 15 minutes before plasma exchange. During the subsequent daily plasma exchange, 11 mg is required to be injected subcutaneously after exchange. After the plasma exchange period, 11 mg is still required to be injected subcutaneously daily for 30 days. If the patient's condition persists, treatment can be extended to 28 days.
Administration
The first dose must be given intravenously by a medical professional, and subsequent doses can be changed to subcutaneous injection in the abdomen. Patients or caregivers need to receive aseptic technique training before performing the operation themselves. Sterile water for injection should be used when reconstituting the drug, avoid shaking, and use it immediately after the solution is transparent and colorless.
Correct usage and dosage are the key to the efficacy of Caplacizumab, and it is equally important to understand its possible side effects and precautions. The following will explain the relevant content in detail.
Side effects and precautions of Caplacizumab
Caplacizumab may cause some adverse reactions during treatment, and special attention should be paid to the related risks when using it.
Common side effects
The most common side effects include epistaxis, headache, and gingival bleeding, with an incidence of about 15%. If serious side effects such as bone marrow suppression, liver damage, or allergic reactions occur, the drug should be discontinued immediately and medical attention should be sought.
Precautions
Caplacizumab increases the risk of bleeding, so it should be avoided in combination with antiplatelet or anticoagulant drugs. The drug should be discontinued 7 days before surgery or invasive procedures. Pregnant women, breastfeeding women and patients with liver damage should use it with caution and closely monitor for signs of bleeding.
Understanding the side effects and precautions of Caplacizumab will help patients and medical staff better manage the treatment process and clarify the safety of medication.
